Načítá se...
PS2-29: KRAS Testing in Metastatic Colorectal Cancer: The CERGEN-C Comparative Effectiveness Study
Genetic testing to inform health professionals and patients of disease risk, diagnostic, prognostic, or treatment information such as KRAS mutation testing to determine colorectal cancer (CRC) treatment is an evolving health care approach. KRAS, a pharmacogenomic marker normally expressed in wild ty...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Marshfield Clinic
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3251389/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3121/cmr.2011.1020.ps2-29 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|